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Background: Local, sustained delivery of cytokines at a tumor can enhance induction of
antitumor immunity and may be a feasible neoadjuvant immunotherapy for breast cancer. We
evaluated the ability of intratumoral poly-lactic-acid-encapsulated microspheres (PLAM) containing
interleukin 12 (IL-12), tumor necrosis factor  (TNF-), and granulocyte-macrophage colony
stimulating factor (GM-CSF) in a murine model of breast cancer to generate a specific antitumor
response.
Methods: BALB/c mice with established MT-901 tumors underwent resection or treatment with
a single intratumoral injection of PLAM containing IL-12, TNF-, or GM-CSF, alone or in
combination. Two weeks later, lymph nodes and spleens were harvested, activated with anti-CD3
monoclonal antibodies (mAb) and rhIL-2, and assessed for antitumor reactivity by an interferon 
(IFN) release assay. Tumor-infiltrating lymphocyte (TIL) analysis was performed on days 2 and
5 after treatment by mechanically processing the tumors to create a single cell suspension, followed
by three-color fluorescence-activated cell sorter (FACS) analysis.
Results: Intratumoral injection of cytokine-loaded PLAM significantly suppressed tumor growth,
with the combination of IL-12 and TNF- leading to increased infiltration by polymorphonuclear
cells and CD8 T-cells in comparison with controls. The induction of tumor-specific reactive
T-cells in the nodes and spleens, as measured by IFN- production, was highest with IL-12 and
TNF-. This treatment resulted in resistance to tumor rechallenge.
Conclusions: A single intratumoral injection of IL-12 and TNF-–loaded PLAM into a breast
tumor leads to infiltration by polymorphonuclear cells and CD8 T-cells with subsequent tumor
regression. In addition, this local therapy induces specific antitumor T-cells in the lymph nodes and
spleens, resulting in memory immune response.
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Although adjuvant chemotherapy and hormonal ther-
apy have improved the overall survival of breast cancer
patients after surgery, the persistence of tumor cells
remains a major cause of recurrence and death.1 Many of
these disseminated tumor cells rest in the G0 phase of the
cell cycle.1–3 Because these nonproliferating cells are
often resistant to chemotherapeutic agents,2,3 many in-
vestigators have looked toward immunotherapy in the
adjuvant setting as an alternative approach to reducing
recurrence rates.
Breast cancer presents several unique challenges to the
use of immunotherapy. Only a few tumor antigens have
been identified in breast cancer, and many of these are
expressed in only a relatively small fraction (20% to
30%) of breast tumors,4 hampering the success of peptide
vaccines or allogeneic cellular vaccines. Autologous tu-
mor cell vaccines have been investigated but have dem-
onstrated disappointing clinical responses.5 More prom-
ising results have been demonstrated with the use of
genetically modified tumor cell vaccines, but this re-
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quires the creation of cell lines for ex vivo manipulation.
This has been extremely difficult with breast cancer,
where less tumor is available for procurement and the
establishment of cell lines has proved challenging. In
addition, ex vivo genetic manipulation can be associated
with limited transfection efficiency and is costly and
time-consuming. All these factors limit its applicability
to the clinical setting. The adenoviral delivery of genes
encoding cytokines directly to the tumor in situ may
circumvent some of these problems but carries several
safety concerns.
We have previously described our experience with the
intratumoral injection of cytokine-encapsulated biode-
gradable polymer microspheres, demonstrating that the
local and sustained release of interleukin 12 (IL-12) in
the tumor microenvironment results in long-term, tumor-
specific immunity.6 Utilized in the neoadjuvant setting,
intratumoral injection of IL-12-loaded microspheres into
the tumor prior to surgical resection was able to decrease
both local and distant tumor recurrence.7 Given the lim-
itations of many immunotherapeutic approaches and the
ease of direct intratumoral injections, the use of cyto-
kine-loaded microspheres seems well-suited to the treat-
ment of breast cancer. To investigate this, we evaluated
the effect of intratumoral injections of cytokine-loaded
microspheres on the subcutaneous growth of the murine
MT-901 breast tumor and the stimulation of both a
regional and systemic tumor-specific immune response.
We report here that the intratumoral delivery of various
cytokine-loaded poly-lactic-acid microspheres (PLAM)
can eradicate established tumors and result in signifi-
cantly enhanced T-cell reactivity of tumor-draining
lymph node (TDLN) cells and splenocytes. PLAM
loaded with the combination of IL-12 and TNF- yielded
greater local and systemic response than either alone.
MATERIALS AND METHODS
Animals
Six- to 8-week-old female BALB/c mice were pur-
chased from The Jackson Laboratory (Bar Harbor, NE)
and maintained in specific pathogen-free conditions at
the Animal Maintenance Facility of the University of
Michigan Medical Center.
Tumors
MT-901 is a subline of a murine tumor cell line
derived from a dimethylbezanthracene-induced mam-
mary carcinoma in the BALB/c strain.8,9 This tumor is
weakly immunogenic and expresses MHC class I but not
MHC class II molecules. RENCA is an immunogenic
murine renal cell carcinoma of spontaneous origin in the
BALB/c strain.10 Line-1 is a BALB/c lung alveolar car-
cinoma cell line.11 Cell lines were maintained in com-
plete media consisting of RPMI 1640 supplemented with
10% heat-activated fetal bovine serum, .1 mM nonessen-
tial amino acids, 1 M sodium pyruvate, 100 g/mL
streptomycin, 100 units/mL penicillin, 50 g/mL genta-
mycin, and .5 g/mL fungizone, all from Life Technol-
ogies (Grand Island, NY). In vivo generation of tumors
was accomplished by subcutaneous injection of BALB/c
mice with 3  106 viable MT-901 cells. Tumors were
measured every other day in two perpendicular dimen-
sions (a  length, b  width) with a Vernier caliper, and
the size was recorded as volume (mm3, as calculated by
a*b2/2). Statistical significance between groups (n  5)
was calculated with an unpaired Student’s t-test, with a
P value  .05 considered statistically significant.
Microspheres
A phase-inversion nanoencapsulation technique was
used for encapsulation of cytokines, as described previ-
ously.12 In brief, bovine serum albumin (BSA, RIA
grade; Sigma Chemical Co., St. Louis, MO), PLA {Mr
24,000 and Mr 2,000 [1:1, w/w], Birmingham Polymers,
Birmingham, AL}, and recombinant cytokine in methyl-
ene chloride (Fisher, Pittsburgh, PA) were rapidly
poured into petroleum ether (Fisher) for formation of
microspheres. Microspheres were filtered and lyophi-
lized overnight for complete removal of solvent. Four
formulations containing 1% BSA (w/w) were produced:
(1) control (no cytokines); (2) murine IL-12 {5 g/mg
of PLA; RandD Systems, Minneapolis, MN); (3) murine
granulocyte-macrophage colony stimulating factor (GM-
CSF: 5 g/mg of PLA; Biosource International, Cam-
arillo, CA); and (4) murine tumor necrosis factor 
(TNF-: 5 g/mg of PLA; RandD Systems). Scanning
electron micrographs previously demonstrated that these
microspheres are 1–5 m in diameter and are easily
injectable with a 27-gauge needle.
Tumor-Draining LN Cells and Activation
At varying time points after inoculation, tumor-drain-
ing LN cells (TDLN) were removed aseptically. Lym-
phoid cell suspensions were prepared by mechanical
dissociation with 25-gauge needles and pressed with the
blunt end of a 10-mL plastic syringe in RPMI 1640. The
cells were activated with 1 g/mL anti-CD3 monoclonal
antibody (mAb) immobilized in 24-well plates (4  106
cells/2 mL/well) for 2 days.13 The LN cells were subse-
quently cultured in recombinant human IL-2 (Chiron
Therapeutics, Emeryville, CA) at 60 IU/mL IL-2 for 3
days at 2  105 cells/mL.
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Splenocytes and Activation
Spleen cells obtained from the BALB/c mice were
treated with ammonium chloride-potassium lysis buffer
(.83% ammonium chloride, .1% KHCO3, and .004%
EDTA) for 1 minute to deplete erythrocytes and were
washed twice with HBSS. Splenocytes were then acti-
vated with 1 g/mL anti-CD3 mAb immobilized in 24-
well plates (4  106 cells/2 mL/well) for 2 days.13 The
LN cells were subsequently cultured in 60 IU/mL IL-2
for 3 days at 2  105 cells/mL.
Measurement of In Vitro Cytokine Release
Activated TDLN or splenocytes (1  106) were cocul-
tured with 5  105 MT-901 tumor cells irradiated to
15,000 cGy in 2 mL of complete media (CM) per well of
a 24-well tissue culture plate. IL-2 (4 IU/mL) was added
at the beginning of the culturing for 48 hours at 37°C. the
supernatants were collected and, after centrifugation, an-
alyzed for interferon- (IFN) with commercially avail-
able ELISAs from PharMingen (San Diego, CA). A
standard curve starting at 1000 U/mL was established, with
11 serial twofold dilutions performed. Experimental values
were computed with the use of regression analysis.
Tissue Processing for Tumor-Infiltrating
Lymphocyte (TIL) Analysis
MT 901 tumors were harvested on days 2 and 5 after
microsphere injection. The tumor and surrounding tissue
(within 2 mm of tumor) were removed, minced with
scissors to 1-mm3 pieces, and processed mechanically
with a Medimachine (DakoUSA, Carpinteria, CA). Pro-
cessing involved placing the tissue in a microblade-
equipped polyethylene chamber (Medicon; CON-
SULT.S., Torino, Italy) 35 M in size, adding .5 mL of
PBS, and cycling the sample in the Medimachine for 45
seconds. The contents of the Medicon were collected via
a 1-cc syringe and passed through a 50-M filter to
create a single cell suspension. The processing was per-
formed twice for each sample.
Fluorescence-Activated Cell Sorter (FACS) Analysis
Processed tumor was enumerated for cell counts and
then stained for three-color FACS analysis with the flu-
orescein isothiocyanate(FITC)-conjugated mAb anti-
CD8, phycoerythrin(PE)-conjugated mAb anti-CD4, PE-
conjugated mAb NK1.1, PE-conjugated mAb GR-1, PE-
conjugated mAb DX5, and CyChrome(CYC)-conjugated
FIG. 1. Inoculation of MT-901 with cytokine-loaded PLAM induces tumor-specific pre-effector cells both regionally and systemically. BALB/c
mice (5 mice per group) were co-inoculated with 3  106 viable MT-901 cells and poly-lactic-acid microspheres encapsulating IL-12, TNF-, and
GM-CSF alone or in combination. Control mice were co-inoculated with BSA-loaded microspheres. Nine days later, TDLN and spleens were removed
aseptically. Lymphoid single-cell suspensions were activated with anti-CD3 mAb for 2 days and then cultured in 60 IU/mL IL-2 for 3 days. Activated
TDLN or splenocytes were cocultured with irradiated MT-901 or RENCA tumor cells. The supernatants were collected and analyzed for IFN
production. Control or naïve lymphoid cells also did not release cytokines. (A) TDLN from mice inoculated with MT-901 and PLAM loaded with
the combination of IL-12 and GM-CSF or IL-12 and TNF- revealed the tumor-specific release of IFN in response to MT-901 tumor cells and not
to Renca cells. (B) Splenocytes from mice inoculated with MT-901 and PLAM loaded with the combination of IL-12 and GM-CSF or IL-12 and
TNF- also showed a dramatic increase in the release of IFN in response to MT-901 tumor cells but not Renca cells. In both the TDLN and spleens,
the highest tumor-specific response was seen with PLAM loaded with the combination of IL-12 and TNF-. Error bars represent standard deviation (SD).
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mAb anti-CD45 (all obtained from PharMingen). Isotype
controls for each of the antibodies were used to define
specific binding. All samples were fixed in a 2% buff-
ered formalin solution and read 24 hours after labeling.
Prior to analysis on a Coulter XL (Beckman Coulter,
Chaska, MN), a known quantity of 15 m polystyrene
microbeads (Bangs Laboratories, Fishers, IN) were
added to each sample to calculate the absolute number of
cells of interest during analysis, with use of the following
formula: {number of events of interest} * {number of
beads added to sample} / {number of beads sampled}.
Analysis of tumor tissue involved the collection of more
than 1,500,000 events and use of the WinList 5.0 pro-
gram (Verity Software House, Topsham, ME). CD4,
CD8, polymorphonuclear (PMN), and natural killer
(NK) cell events were gated only on CD45-positive
events. Absolute cell counts were expressed as a function
of individual tumor size.
Statistical Analysis
Statistical significance between groups was calculated
with an unpaired Student’s t-test, with a P value  .05
considered statistically significant.
RESULTS
Inoculation of MT-901 with IL-12 and GM-CSF or
TNF-–loaded PLAM induces tumor-specific pre-effec-
tor cells both regionally and systemically. To identify the
cytokines (alone or in combination) that could stimulate
a regional or systemic response, mice were inoculated
with MT-901 tumor cells in the flank in combination
with 1 mg of cytokine-encapsulated microspheres (for
combination therapy, .5 mg of each cytokine was used;
for control groups, BSA-loaded microspheres were
used). Treatment groups comprised five mice each. Nine
days later the mice were killed and had TDLN and
spleens harvested for anti-CD3/IL-2 activation. TDLN
from mice inoculated with MT-901 alone demonstrated
no release of IFN in response to tumor stimulation. In
this assay, control or naïve lymphoid cells also did not
release cytokines. TDLN from mice inoculated with MT-
901 and either IL-12-loaded PLAM or TNF--loaded
PLAM showed an increased release of IFN in response
to tumor stimulation, in comparison with nonstimulated
lymphocytes. This response, however, was nonspecific,
as it was stimulated by both MT-901 and Renca cells.
TDLN from mice inoculated with MT-901 and PLAM
loaded with the combination of IL-12 and GM-CSF or
the combination of IL-12 and TNF- revealed the tumor-
specific release of IFN only in response to MT-901
tumor cells and not to Renca cells (Fig. 1A).
Splenocytes from mice inoculated with MT-901 alone
also demonstrated minimal release of IFN in response
to tumor stimulation. Splenocytes from mice inoculated
with MT-901 and IL-12-loaded PLAM showed a mild
tumor-specific increase in IFN, while those inoculated
with TNF- did not. Again, however, splenocytes from
mice inoculated with MT-901 and PLAM loaded with
the combination of IL-12 and GM-CSF or IL-12 and
TNF- resulted in a dramatic increase in the release of
IFN in response to MT-901 tumor cells but not Renca
cells (Fig. 1b). In both the TDLN and spleens, the highest
tumor-specific response was seen with PLAM loaded
with the combination of IL-12 and TNF-.
Treatment of Established Tumors with an
Intratumoral Injection of IL-12 and GM-CSF or
TNF--Loaded PLAM Causes Tumor Regression
On the basis of these results, we next sought to inves-
tigate whether this approach would be effective in the
treatment of established tumors. Balb/c mice were inoc-
ulated subcutaneously with MT-901 cells in the right
flank. Treatment groups comprised five mice each.
Eleven days after inoculation, when all mice had palpa-
ble subcutaneous tumors, mice were treated by intratu-
moral injection of cytokine-loaded microspheres. Con-
trol mice were injected with a single injection of BSA-
loaded microspheres at a dose of 2 mg PLA/tumor. Mice
FIG. 2. Effect of intratumoral injection of cytokine-loaded PLAM on
primary tumor growth. Balb/c mice (five to 10 mice per group) were
inoculated subcutaneously with 3  106 MT-901 cells in the right
flank. Eleven days later, palpable tumors were treated by intratumoral
injection of cytokine-loaded microspheres (or BSA-loaded micro-
spheres in control mice). Tumors were measured every other day in two
perpendicular dimensions (a  length, b  width) and the size was
recorded as a volume (mm3), as calculated by a*b2/2. Tumor suppres-
sion was seen with intratumoral injection of IL-12 alone and TNF-
alone. Tumor regression was seen with the intratumoral injection of
IL-12 in combination with GM-CSF and TNF-. The addition of
TNF- to IL-12 significantly improved the results in comparison with
IL-12 alone (P  .03). Error bars represent the standard deviation (SD).
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treated with IL-12 or TNF-–loaded microspheres were
also treated at a dose of 2 mg PLA/tumor. Mice treated
with the combination of IL-12 and GM-CSF or IL-12
and TNF- were treated by two injections of each cyto-
kine at a dose of 1 mg PLA/tumor. By day 25 after
inoculation, tumor size in the untreated group averaged
526 mm3 (Fig. 2). Tumor suppression was seen with both
intratumoral injection of IL-12 (average tumor size, 181
mm3; P  .04) and TNF- (average tumor size, 153
mm3; P  .03). Tumor regression was seen with the
intratumoral injection of IL-12 in combination with GM-
CSF (average tumor size, 55 mm3; P  .004 in compar-
ison with controls) and TNF- (average tumor size, 9
mm3; P  .0001 in comparison with controls). The
addition of TNF- to IL-12 significantly improved the
results in comparison with IL-12 alone (P  .03), and
this combination of IL-12 and TNF- resulted in the
highest percentage of tumor-free mice (Fig. 3).
Treatment of Established Tumors with an
Intratumoral Injection of IL-12 and TNF-–Loaded
PLAM Induces Tumor-Specific Pre-effector Cells
both Regionally and Systemically
Mice with MT-901 tumors treated by intratumoral
injection of cytokine-loaded PLAM were killed 14 days
later, and both TDLN and spleens were harvested for
anti-CD3/IL-2 activation. TDLN from mice treated with
BSA-loaded PLAM demonstrated no release of IFN in
response to tumor stimulation. TDLN from mice treated
with either PLAM loaded with the combination of IL-12
and GM-CSF or IL-12 and TNF- showed a dramati-
cally higher release of IFN in response to MT-901
tumor cells than to Line-1 cells (Fig. 4a).
Splenocytes from mice treated with IL-12 or TNF-
alone again demonstrated minimal release of IFN in
response to tumor stimulation. The combination of IL-12
and GM-CSF, which has been effective in previous as-
says, failed to demonstrate a significant systemic re-
FIG. 3. Percentage of mice rendered tumor-free after intratumoral
injection of cytokine-loaded poly-lactic-acid microspheres.
FIG. 4. Treatment of MT-901 tumors with IL-12 and TNF-–loaded PLAM induces systemic tumor specific pre-effector cells. Balb/c mice (five
mice per group) were inoculated subcutaneously with 3  106 MT-901 cells in the right flank. Eleven days later, palpable tumors were treated by
intratumoral injection of cytokine-loaded microspheres (or BSA-loaded microspheres in control mice). TDLN and spleens were harvested and
single-cell suspensions were activated with anti-CD3 mAb for 2 days and then cultured in 60 IU/mL IL-2 for 3 days. Activated TDLN or splenocytes
were cocultured with irradiated MT-901 or Line-1 tumor cells and then analyzed for IFN production. (A) TDLN from mice treated with PLAM
loaded with the combination of IL-12 and GM-CSF or IL-12 and TNF- resulted in a substantial tumor-specific release of IFN in response to
MT-901 tumor cells. The splenocytes of mice treated by PLAM loaded with the combination of IL-12 and GM-CSF failed to demonstrate a significant
antitumor response in splenocytes. (B) Splenocytes from mice treated with IL-12 and TNF-–loaded PLAM showed a significant tumor-specific
release of IFN in response to MT-901 tumor cells. Error bars represent standard deviation (SD).
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sponse in the treatment of an established tumor, as mea-
sured by tumor-specific IFN release in several
experiments. Splenocytes from mice treated with PLAM
loaded with the combination of IL-12 and TNF-, how-
ever, showed a significant tumor-specific release of
IFN in response to MT-901 tumor cells (Fig. 4b).
Intratumoral Injection of Cytokine-Loaded PLAM
Resulted in the Infiltration of PMN Cells and CD8
Cytotoxic T-Cells at the Site of the Tumor
Growth curves after intratumoral injection of cyto-
kine-loaded PLAM suggested that IL-12 or TNF- alone
led to tumor suppression, whereas the combination of
IL-12 and TNF- led to tumor regression (Fig. 2), with
eradication of tumor in 70% of treated mice (Fig. 3).
Tumor regression was seen approximately 3 days after
treatment. To further identify the cellular component of
the immune response responsible for tumor regression,
three-color FACS analysis was used to enumerate the
tumor-infiltrating lymphocytes at days 2 and 5 after
treatment with microspheres encapsulating IL-12,
TNF-, or the combination (Fig. 5). Control mice were
treated with BSA-loaded microspheres. The results are
shown in Fig. 6. Treatment with control microspheres
resulted in minimal amounts of infiltrating lymphocytes
on both day 2 and day 5. Treatment with IL-12 in
combination with TNF- resulted in a statistically sig-
nificant rise in PMN cells within the tumor microenvi-
ronment (P  .04). Despite the fact that the NK-stimu-
lating properties of IL-12 have been well described, NK
FIG. 5. FACS analysis of tumor-infiltrating lymphocytes. Treated MT 901 tumors were removed, processed mechanically, and passed through a
50-M filter to create a single-cell suspension. Cells were then enumerated for cell counts and then stained for three-color FACS analysis with
FITC-conjugated mAb anti-CD8, PE-conjugated mAb anti-CD4, and CYC-conjugated mAB anti-CD45. Isotype controls for each of the antibodies
were used to define specific binding. All samples were fixed in a 2% buffered formalin solution and read 24 hours after labeling. Prior to analysis,
a known quantity of 15 m polystyrene microbeads was added to each sample to calculate the absolute number of cells of interest during analysis.
CD4 and CD8 cells were stringently gated on the high CD45 population to eliminate background signal from specific binding.
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cells did not appear to be responsible for tumor regres-
sion, as there was no change in NK cells within the
treated tumors for any of the groups. IL-12 or TNF-
alone had no effect on CD4 T-helper cells. The com-
bination appeared to lead to an increase in CD4 infil-
tration, but this was not statistically significant (P  .18).
However, both IL-12 and TNF- alone led to significant
increases in tumor infiltration by CD8 cytotoxic T-cells
(P  .02 and P  .004, respectively). The intratumoral
injection of PLAM loaded with the combination of IL-12
and TNF- led to a statistically significant increase in
CD8 cells in comparison with the control groups (P 
.001) or either cytokine-alone group (P  .002 for IL-12
alone and P  .006 for TNF- alone).
Intratumoral Injection of IL-12 and TNF-–Loaded
PLAM Resulted in Immune Memory
In a separate experiment, Balb/c mice were inoculated
with a subcutaneous injection of 3  106 MT-901 cells
in the right flank. On day 11, when all mice had palpable
subcutaneous tumors, mice underwent either surgical
excision of the tumor or injection with 1 mg PLA/tumor
of IL-12 and either TNF- (1 mg PLA/tumor) or GM-
CSF (1 mg PLA/tumor) (10 mice per group). Three
weeks later, all tumor-free mice were re-inoculated on
the opposite flank with an identical tumorigenic dose of
MT-901 cells. By day 10 after rechallenge, 80% of mice
treated by surgical excision had tumors, whereas none of
the mice treated by intratumoral IL-12 and TNF-
PLAM had evidence of tumor growth (Fig. 7) (P  .002
by 2 test).
DISCUSSION
Slow-release polymer microspheres can be used to
achieve the paracrine delivery of cytokines to the tumor
microenvironment after a single intratumoral injection.
This approach has the potential to generate an effective
systemic response with minimal side effects.14 The re-
sults described here demonstrate that a single injection of
IL-12 and TNF- encapsulated microspheres into a pri-
mary breast tumor initiates infiltration with PMN cells
and CD8 cytotoxic T-cells, leading to regression of the
tumor. In addition, this process can induce tumor-spe-
FIG. 6. Intratumoral injection of cytokine-loaded PLAM resulted in the infiltration of PMN cells and CD8 cytotoxic T-cells at the site of the tumor.
Balb/c mice (five mice per group) were inoculated subcutaneously with 3  106 MT-901 cells in the right flank. Twelve days later, palpable tumors
were treated by intratumoral injection of cytokine-loaded microspheres (or BSA-loaded microspheres in control mice). Mice were killed on days 2
and 5 after treatment. Treatment with IL-12 in combination with TNF- resulted in a statistically significant rise in PMN cells within the tumor
microenvironment (P  .04). There was no change in NK cells within the treated tumors for any of the groups. IL-12 or TNF-a alone had no effect
on CD4 T-helper cells. The combination appeared to lead to an increase in CD4 infiltration, but this was not statistically significant (P  .18).
Both IL-12 and TNF- alone led to significant increases in tumor infiltration by CD8 cytotoxic T-cells (P  .02 and P  .004, respectively). The
intratumoral injection of PLAM loaded with the combination of IL-12 and TNF- led to a statistically significant increase in CD8 cells in comparison
with control groups (P  .001) or either cytokine alone (P  .002 for IL-12 alone and P  .006 for TNF- alone).
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cific T-cells both regionally—in the tumor-draining
lymph nodes—and systemically in the spleen. This im-
mune response results in a memory response, as evi-
denced by resistance to tumor rechallenge.
We have previously described an in situ cytokine
delivery system utilizing slow-release polymer micro-
spheres. This achieves a sustained release of cytokines
into the tumor microenvironment, resulting in a local
inflammatory response. We hypothesize that the necrosis
of the primary tumor provides large doses of tumor
antigen locally and the subsequent induction of an adap-
tive tumor-specific T-cell response.6,15 In our initial ex-
periments IL-12 demonstrated the most promise for sin-
gle cytokine therapy with this approach6 and has shown
tremendous potential in multiple models.16–19 IL-12 is a
potent proinflammatory cytokine, with the ability to in-
duce rapid activation of innate and anti-angiogenic
mechanisms21,22 and to promote the development of a
Th1-type cellular response.23 In this series of experi-
ments, intratumoral injection of IL-12-loaded PLAM did
demonstrate some benefit, causing a significant tumor
infiltration of CD8 cells and tumor regression in com-
parison with controls, but it did not result in an effective
systemic antitumor response, particularly when used in
the treatment of established tumors.
Several groups using different models of cytokine-
based immunotherapies have demonstrated that the com-
bination of IL-12 with other pro-inflammatory cytokines
can improve this response. In a previous report, we
demonstrated that the combination of IL-12 and GM-
CSF was significantly better than IL-12 alone in our
model, resulting in adaptive antitumor responses that
could eradicate disseminated disease.15 Other researchers
have also demonstrated the benefits of combining IL-12
with GM-CSF,24,25 as well as with TNF-.25-28 This
study confirms that in a murine model of breast cancer,
PLAM loaded with the combination of IL-12 and GM-
CSF was effective and significantly better than IL-12
alone. Co-inoculation with MT-901 cells led to a re-
gional and systemic tumor-specific response and also
caused tumor regression when injected intratumorally
into established tumors. However, the most effective
combination was IL-12 and TNF-, surpassing IL-12
and GM-CSF in both tumor regression and the percent-
age of mice cured, as well as the regional and systemic
response. In addition, this combination was shown to
result in immune memory capable of preventing tumor
growth at a subsequent rechallenge. The success of these
combinations is not surprising, given that TNF- syner-
gizes with IL-12 for IFN- production, skewing a CD4
FIG. 7. Mice cured by intratumoral injection of IL-12 and TNF-–loaded PLAM develop long-term immunity in comparison with the results of
surgical excision alone. Balb/c mice (10 mice per group) were inoculated with a subcutaneous injection of 3  106 MT-901 cells in the right flank.
On day 12, when all mice had palpable subcutaneous tumors, mice underwent either surgical excision of the tumor or injection with PLAM loaded
with IL-12 and TNF- or GM-CSF. Three weeks later, all successfully treated mice were then re-inoculated on the opposite flank with an identical
tumorigenic dose of MT-901 cells. By day 10 after rechallenge, 80% of mice treated by surgical excision had tumors but none of the mice treated
by intratumoral IL-12 and TNF- PLAM had evident tumor growth (P  .002 by 2).
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cell response to Th1 in BALB/c mice, and that both
cytokines synergize with IL-12 in inducing cytotoxic
T-lymphocytes.29 It is possible that the triple combina-
tion of IL-12, TNF-, and GM-CSF may be the most
potent combination,25 but this was not investigated in
this series of experiments. The combination of TNF-
and GM-CSF was also studied but did not demonstrate
any significant benefit (data not shown).
These results suggest that a single intratumoral injec-
tion of IL-12 and TNF-–loaded PLAM into a primary
breast cancer prior to surgical excision can lead to a
tumor-specific immune response. We have previously
demonstrated that this systemic antitumor response stim-
ulated in the neoadjuvant setting is capable of eradicating
micrometastatic disease, thus reducing both local and
distant recurrence.7 There is evidence that immunother-
apy may be most successful in the minimal residual-
disease setting30,31 and is less likely to be effective in the
setting of advanced disease.14,32,33 Therefore, stimulating
an immune response in the neoadjuvant or adjuvant
period appears to be the most likely approach for clinical
impact.
In conclusion, the local and sustained release of IL-12
and TNF- within a breast tumor, as can be accom-
plished by a single intratumoral injection of the cyto-
kines encapsulated in poly-lactic-acid microspheres, can
lead to regression of the primary tumor and, more im-
portant, the generation of a tumor-specific T-cell-medi-
ated immune response. This approach holds several ad-
vantages regarding clinical feasibility in comparison
with many immunotherapeutic approaches being inves-
tigated in breast cancer. Several questions remain regard-
ing the clinical application of cytokine-encapsulated mi-
crospheres, including the potential impact of surgery,
radiation therapy, or systemic therapies on the immune
response. Further investigation into the mechanisms in-
volved in both the local and distant effects are warranted
so that this approach can be translated to the clinic.
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